On the medication of COVID-19 in diabetes combined with hypertension, GLP-1R agonists, DPP-4 inhibitors, or pioglitazone were associated with significant reductions in hospital admissions, respiratory complications, and mortality, and may improve COVID-19 outcomes in patients with T2DM (16). This evidence concerns the gene GLP1R and COVID-19.